BTG2 Antibody

Code CSB-PA124546
Size US$166
Order now
Image
  • Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human liver cancer tissue, Primary antibody: CSB-PA124546(BTG2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
BTG2
Alternative Names
B cell translocation gene 2 antibody; BTG family member 2 antibody; Btg2 antibody; BTG2_HUMAN antibody; Nerve growth factor inducible anti proliferative antibody; NGF inducible anti proliferative protein PC3 antibody; NGF-inducible anti-proliferative protein PC3 antibody; PC3 antibody; Pheochromacytoma cell 3 antibody; Protein BTG2 antibody; TIS21 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Fusion protein of Human BTG2
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
WB 1:200-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors. Modulates transcription regulation mediated by ESR1. Involved in mitochondrial depolarization and neurite outgrowth.
Gene References into Functions
  1. oncogenic miR-25-3p directly targets BTG2 in TNBC. Further studies revealed that the biological effects of miR-25-3p on TNBC cell proliferation and apoptosis were mediated through regulation of BTG2 and subsequent activation of AKT and ERK-MAPK signaling pathway. PMID: 29310680
  2. Open data and immunohistochemical analysis were performed to confirm the role of TIS21(/BTG2) expression in various human breast cancer tissues. It was observed that TIS21(/BTG2) inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression. PMID: 29808317
  3. we found that miR-27-3p was overexpressed in gastric cancer tissues and cell lines and that BTG2 was a direct and functional target of miR-27a-3p in gastric cancer PMID: 27409164
  4. decreases tumorigenesis of hepatocellular carcinoma cell line side population cells PMID: 29098552
  5. Effect of TIS21 on the regulation of p53 activity was confirmed by knockdown of TIS21 expression by RNA interference. PMID: 27208501
  6. Data indicate that BTG2, MAP3K11, RPS6KA1 and PRDM1 as putative targets of microRNA miR-125b. PMID: 27613090
  7. The results indicated that BTG2 expression was downregulated in skin cancer cell lines. Overexpression of BTG2 significantly inhibited cell proliferation, cell cycle progression, and the invasion and migration of skin cancer cells. PMID: 27510158
  8. Overexpression of BTG2 inhibited the proliferation and migration/invasion of human osteosarcoma cells in vitro PMID: 26722427
  9. clinical data support conclusions generated from patient-derived xenograft models and indicate that BTG2 expression is a candidate prognostic biomarker for TNBC. PMID: 26818199
  10. miR-21 was found to be overexpressed and BTG2 was found to to be downregulated in HepG2 liver cancer cells. PMID: 26151427
  11. BTG2 stimulates mRNA deadenylation via CAF1 activation through interaction with PABPC1. Interaction of BTG2 with the first RRM domain of PABPC1 is required for BTG2 to control cell proliferation. PMID: 26912148
  12. SETD1A suppresses BTG2 expression through its induction of several BTG2-targeting miRNAs. PMID: 26394836
  13. Results indicate that miR27a and BTG2 promote the migration and the growth of glioblastoma (GBM) cells and miR27a directly targets BTG2 in GBM cells. PMID: 25626081
  14. Our results indicated that cisplatin attenuates prostate cancer cell proliferation partly mediated by upregulation of BTG2 through the p53-dependent pathway or p53-independent NFkappaB pathway. PMID: 24981574
  15. In this review, we summarize the latest findings in BTG2 studies, highlighting the mechanisms for the regulatory effects of microRNAs (miRNAs) on BTG2 gene expression in the most common human cancers. PMID: 25405282
  16. By applying loss-and-gain function analysis in NSCLC cell lines, we demonstrated that miR-25-BTG2 axis could directly regulated BTG2 expression and affect radiotherapy sensitivity of NSCLC cells. PMID: 25576360
  17. An association with Graves disease was shown for several SNPs in BTG2. PMID: 24780075
  18. BTG2 expression was inversely correlated with increased expression of the DNA methyltransferases DNMT1 and DNMT3a in MIBC, but not NMIBC, suggesting a potential role for BTG2 expression in muscle invasion of bladder cancer PMID: 25284287
  19. Reactive oxygen spieces regulate Btg2/TIS21/PC3 expression via Protein kinase C-NFkappaappaB pathway. PMID: 23876794
  20. TIS21 decreased interleukin-6 (IL-6) expression in human dermal fibroblast. PMID: 23917204
  21. miR-21 is involved in MNNG-induced gastric carcinogenesis in vivo and in vitro via FASLG/BTG2 pathway. PMID: 24821435
  22. BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. PMID: 24698107
  23. pro-apoptotic pathway of CRP-CD32-Nox2-p53-BTG2 may contribute to the retardation of the atherogenic process PMID: 24440351
  24. Data indicate that the pattern of B cell translocation gene 2 (BTG2) protein expression was exactly the opposite of miRNA-21 expression in lung cancer cells. PMID: 23857284
  25. BTG2 mediates crosstalk between PI3K-Akt1 and NF-kappaB pathways, which regulates p53-independent induction of G2/M phase arrest both in normal and cancer cells. PMID: 24047462
  26. BTG2 can improve the radiosensitivity of breast cancer cells by affecting cell cycle distribution, enhancing radiation-induced apoptosis, and inhibiting DNA repair-related protein expression. PMID: 24308156
  27. TIS21 suppresses invadopodia formation as well as invasion activity along with F-actin remodeling. PMID: 23907596
  28. Downregulation of the basal protein B-cell translocation gene 2 is associated with prostate cancer transformation and progression. PMID: 22614007
  29. These results indicate that endogenous BTG2 expression contributes to the migratory potential of bladder cancer cells. Moreover, high levels of BTG2 in bladder cancers are linked to decreased cancer-specific survival. PMID: 23299537
  30. TIS21 regulates DNA double strand break repair and apoptosis via increasing Mre11 methylation. PMID: 23089312
  31. study reveals that BTG2 negatively regulated cancer cell migration by inhibiting Src activity through downregulation of reactive oxygen species generation in mitochondria PMID: 22562501
  32. MIR32 is upregulated in prostate cancer and regulates expression of BTG2. PMID: 22266859
  33. a novel role for BTG2 as a co-activator for NFE2L2 in up-regulating cellular antioxidant defenses. PMID: 22493435
  34. Results suggest that the overexpression of B cell translocation gene 2 (BTG2) may inhibit the growth, proliferation, and invasiveness of the A549 lung cancer cell line. PMID: 22392501
  35. Estrogen receptor beta causes a G2 cell cycle arrest by inactivating CDK1 through the repression of cyclin B1 and stimulation of GADD45A and BTG2 expression. PMID: 21120602
  36. These findings, for the first time, demonstrate that BTG2 complexes with AR via an LxxLL-dependent mechanism and may play a role in prostate cancer via modulating the AR signaling pathway. PMID: 21172304
  37. The neutralization of Pin1 by BTG2 provides a critical mechanism to maintain senescent arrest in the presence of mitogenic signals in normal primary fibroblasts. PMID: 20569234
  38. The influence of BTG2 on the growth, proliferation, apoptosis, invasion and cell cycle of the gastric cancer cell lines, was investigated. PMID: 19728149
  39. High-level BTG2 protein expression correlates with prolonged survival in patients with breast carcinoma. PMID: 20553615
  40. miR-18 may negatively regulate the expression of BTG2 in HepG2 cells. PMID: 19203451
  41. Transient expression assays with BTG2/TIS21/PC3 promoter deletions and electrophoretic mobility shift analysis identified a major wild-type p53 response element located -74 to -122 relative to the start codon. PMID: 11814693
  42. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. the C-terminal regions are necessary and sufficient to control the stabilities of BTG1, BTG2, Tob, and Tob2 proteins. PMID: 12135500
  43. BTG2 interacts with the CCR4 complex and has a role in cell-cycle regulation PMID: 12771185
  44. deregulation of BTG2 may be an important step in the development of mammary tumors PMID: 15378000
  45. DeltaNp73alpha not only acts as an inhibitor of p53/TAp73 functions in neuroblastoma tumors, but also cooperates with wt-p53 in playing a physiological role through the activation of BTG2TIS21/PC3 gene expression PMID: 15741235
  46. binding of tis21/BTG2/pc3 to Pin-1 or cyclin B1-Cdc2 complex and induction of mitochondrial depolarization are responsible for the antiproliferative effects of EGF in human tumor cells PMID: 15788397
  47. BTG2 expression was found to be significantly reduced in a large proportion of human kidney and breast carcinomas, suggesting that BTG2 is a tumor suppressor that links p53 and Rb pathways in human tumorigenesis. PMID: 16418486
  48. BTG2 contributes to retinoic acid activity by favoring differentiation through a gene-specific modification of histone H4 arginine methylation and acetylation levels. PMID: 16782888
  49. Reverse-transcription polymerase chain reaction confirmed increased expression of GADD45A, BTG2, PDE4B, and CEBPD and downregulation of TOB1 in skeletal muscle intradialysis. PMID: 16997058
  50. T3 upregulates proliferation of LNCaP cells by downregulating BTG2 gene expression through the consensus TRE pathway. PMID: 18196550

Show More

Hide All

Protein Families
BTG family
Database Links

HGNC: 1131

OMIM: 601597

KEGG: hsa:7832

STRING: 9606.ENSP00000290551

UniGene: Hs.519162

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*